NewLink Inks $13.5M Deal In Investor Suit Over Cancer Drug
Investors in biopharmaceutical company NewLink Genetics Corp. told a Manhattan federal judge that they'd reached a $13.5 million deal to settle their proposed securities class action accusing the company and its...To view the full article, register now.
Already a subscriber? Click here to view full article